期刊
GENETICS IN MEDICINE
卷 16, 期 4, 页码 286-293出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/gim.2013.138
关键词
genetic testing; hypertrophic cardiomyopathy; pathogenicity; SNV
资金
- Australian Prime Minister's Endeavour Award Scholarship
- National Heart Foundation
- National Health and Medical Research Council (NHMRC)
Purpose: Major advances have been made in our understanding and clinical application of genetic testing in hypertrophic cardiomyopathy. Determining pathogenicity of a single-nucleotide variant remains a major clinical challenge. This study sought to reassess single-nucleotide variant classification in hypertrophic cardiomyopathy probands. Methods: Consecutive probands with hypertrophic cardiomyopathy with a reported pathogenic mutation or variation of uncertain significance were included. Family and medical history were obtained. Each single-nucleotide variant was reassessed by a panel of four reviewers for pathogenicity based on established criteria together with updated cosegregation data and current population, based allele frequencies. Results: From 2000 to 2012, a total of 136 unrelated hypertrophic cardiomyopathy probands had genetic testing; of which 63 (46%) carried a least one pathogenic mutation: MYBPC3 (n = 34; 47%). and MYH7 (n = 23; 32%) gene variants together accounted for 79%.; Five variants in six probands (10%) Were reclassified: two variation of uncertain significance were upgraded to pathogenic, one variation of uncertain significance and one pathogenic variant were downgraded to benign, and one pathogenic variant (found in two families) was downgraded to variation of Uncertain significance. None of the reclassifications had any adverse clinical consequences. Conclusion: Given the rapid growth of genetic information available in both disease and normal populations, periodic reassessment of single-nucleotide variant data is essential in hypertrophic cardiomyopathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据